Strongbridge hands off Macrilen to Novo for sizable return

Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO

Read the full 274 word article

User Sign In